



# XXIII PAN AMERICAN SANITARY CONFERENCE

## XLII REGIONAL COMMITTEE MEETING

WASHINGTON, D.C.

SEPTEMBER 1990

Provisional Agenda Item 2.7

CSP23/20, Corrig. (Eng.)

17 September 1990

ENGLISH ONLY

SELECTION OF TWO MEMBER GOVERNMENTS FROM THE REGION OF THE AMERICAS TO THE  
MANAGEMENT ADVISORY COMMITTEE OF THE ACTION PROGRAM ON ESSENTIAL DRUGS

### Corrigendum

Please introduce the following corrections to Document CSP23/20:

Page 1: Second paragraph, first and second lines should read:

"Until August 1988 the Program operated under the direct supervision of the Director-General. At that time, it was incorporated into the newly...."

Page 2: First paragraph, first line, change "Review" to "Advisory."

Second paragraph, first line, change "has" to "in."



# XXIII PAN AMERICAN SANITARY CONFERENCE

## XLII REGIONAL COMMITTEE MEETING

WASHINGTON, D.C.

SEPTEMBER 1990

### Provisional Agenda Item 2.7

CSP23/20 (Eng.)

24 July 1990

ORIGINAL: ENGLISH

### SELECTION OF TWO MEMBER GOVERNMENTS FROM THE REGION OF THE AMERICAS TO THE MANAGEMENT ADVISORY COMMITTEE OF THE ACTION PROGRAM ON ESSENTIAL DRUGS

The objective of the WHO Action Program on Essential Drugs (DAP), established in 1981, is to support Member States in ensuring the regular supply of essential drugs of acceptable quality and low cost to help achieve the goal of Health for All by the Year 2000. The Program addresses the highly complex technological, social, political and economic issues involved in the development and implementation of national drug policies. In recognition of the sensitive and potentially controversial areas covered by the DAP, the WHO Executive Board established a special Ad Hoc Committee on Drug Policies.

Until August 1988 the Program operated under the direct supervision of the Director-General, and was incorporated into the newly established Division of Drug Policy and Management. The Division also includes other Programs concerned with medicinal products: Pharmaceuticals, Biologicals, Traditional Medicine, and Psychotropic and Narcotic Drugs. The integration of all drug-related programs is intended to provide for greater balance in the emphasis laid upon the various elements of WHO's Revised Drug Strategy.

At the Second Meeting of Interested Parties, held in Geneva, 22-24 June 1988, the representative of the Netherlands proposed the establishment of a Management Review Committee similar to the one for the AIDS Program. Such a committee was considered to be needed for discussion of the managerial and policy issues encountered in order to ensure the continuity and coherence of the Essential Drugs Program, which has become a large organization with a wide range of activities funded primarily from sources outside the regular WHO budget. The proposed budget for 1990-1991 totals \$20,688,000.

Revised terms of reference for the Management Review Committee (MAC) were approved at the Third Meeting of Interested Parties, Geneva, 25-26 May 1989 (Annex I). The new committee replaces the irregularly-scheduled Meeting of Interested Parties and has formal responsibility for advising the Director-General on the policy, strategy, financing, management, monitoring and evaluation of the DAP, while the Executive Board Committee on Drug Policies would report to the Executive Board on any matter on drug policy referred to it by the Board. The Chairman of the Executive Board is an ex officio member of the MAC.

The first meeting of the MAC took place in Geneva from 5-6 October. The countries attending (two per Region) had been selected by the Regional Offices from a list proposed by the Director-General. In view of time constraints, that meeting agreed that until the Regional Committees were able to meet and select their representatives on the MAC, those countries invited to attend the first meeting would continue as members of the Committee. That was the situation for the meeting held 28-29 March 1990 in Geneva, in which the Region of the Americas was represented by Bolivia and Jamaica.

In order that the 1991 meeting of the MAC have representative members reflecting the Regional Committee's selection, this question has been included in the provisional agenda. The Pan American Sanitary Conference, acting as the Regional Committee of WHO for the Americas, is requested to select two Member Governments each entitled to designate a person to serve on the MAC, according to the following scheme approved at the first meeting:

"With respect to regional representation the Committee agreed to adopt a system of 'staggered' change of membership to achieve a three-year cycle in which four out of the twelve regional members would be replaced each year. The Chairperson drew lots to determine which regions would be in which of the three categories. The result was as follows:

Category 1: One member for 1 year and 1 member for 2 years:  
Africa, South-East Asia

Category 2: One member for 1 year and 1 member for 3 years:  
Americas, Western Pacific

Category 3: One member for 2 years and 1 member for 3 years:  
Europe, Eastern Mediterranean."

Attached for easy reference is a chart reflecting the above (Annex II).

Based on this scheme, this year the Regional Committee for the Americas, XXIII Pan American Sanitary Conference, will select one Member Government to designate a member of the Management Advisory Committee to serve for a term of one year and will select a second Member Government to designate a Member of the Advisory Committee to serve for a term of three years.

Annexes

## ACTION PROGRAMME ON ESSENTIAL DRUGS

### Terms of reference of the Management Advisory Committee

The Management Advisory Committee (MAC) represents the interests and responsibilities of WHO's external partners collaborating with WHO in its Action Programme on Essential Drugs. It acts as an advisory body to the Director-General of WHO, making recommendations on matters related to the policy, strategy, finance, management, monitoring and evaluation of the WHO's Action Programme on Essential Drugs (DAP).

### Functions

- Review, analyse and guide the programme of activities and related budget of DAP and make appropriate recommendations to the Director-General;
- Review the arrangements envisaged by the Director-General of WHO for financing and managing DAP;
- Review proposed longer-term plans of action and their financial implications;
- Review of financial statements of DAP;
- Review periodic reports evaluating the progress of DAP towards the achievement of its objectives and submit its findings and recommendations to the Director-General;
- Recommend ways of improving, as appropriate, coordination between the activities of DAP and of other relevant programmes and organizations; and
- Consider any other matters relating to DAP referred to it by the Director-General of WHO, the Programme Manager of DAP or any member of the Committee.

In carrying out its function, MAC shall be informed of all policy decisions and recommendations concerning DAP or WHO's Revised Strategy on Drugs (RSD) made by the World Health Assembly and the Executive Board.

### Composition

- The governments of those countries which contributed funding in support of DAP's general budget in the previous fiscal year or which provided bilateral support to developing countries for the formulation or implementation of national drug policies in conformity with WHO's policies on essential drugs;
- Two Member States from each of WHO's six Regions selected by the respective Regional Committees for three-year terms from among those Member States with which DAP is collaborating;

- The four major international organizations collaborating in the implementation of WHO's RSD, namely - UNDP, UNICEF, UNIDO and the World Bank; and
- The Chairman or the Vice-Chairman of the Committee on Drug Policies of the Executive Board, or a member designated by the Chairman.

Representatives of governments and intergovernmental organizations not included on MAC as well as nongovernmental organizations involved in the RSD may, on request, be granted observer status.

The identity of those countries contributing funding in support of DAP's general budget and those providing bilateral support in the above manner, and hence their eligibility for membership in MAC, shall be ascertained annually. Members selected from the six Regions of WHO may be reappointed. The four major international organizations shall be considered to have permanent seats for as long as they continue to participate in DAP in support of WHO's RSD. The Chairperson of MAC should, in principle, be a government representative and shall be elected from and by members of MAC for a period of two years, but, while eligible for re-election, may not serve consecutive terms. The Chairperson shall preside over meetings of MAC and undertake whatever additional duties may be assigned by MAC, in agreement with the Director-General of WHO.

### Operation

The MAC shall meet once a year. The Meeting shall concentrate on reviewing DAP's programme for that year in light of the financial support that will have been pledged and the past, present, and future coordination of external support for DAP's principal areas of activity (country support, development work and operational research). The meeting shall also review and guide the following year's programme and related budget. The MAC may also meet more often upon the proposal of either its Chairperson or the Director-General of WHO, and with the latter's agreement. The MAC shall decide its method of work, which may include the establishment of a number of functional subcommittees. All such subcommittees will have an advisory role to MAC. Each MAC meeting shall elect a rapporteur from among its members who shall assist in ensuring that the decisions reached by the meeting are adopted and recorded before its closure. The MAC should, wherever possible, adopt its conclusions by consensus. The Programme Manager of DAP shall be the Secretary of MAC.

For these purposes, MAC shall be assisted in its endeavours by the provision by WHO of whatever secretariat and other support services may be considered necessary and reasonable.

### Review

At the second meeting of the MAC, its terms of reference as set out above will be reviewed in the light of members' experience.

Management Advisory Committee (MAC) of the  
Action Programme on Essential Drugs

REGIONAL REPRESENTATION  
1991 - 1993

	1991	1992	1993
AFR	Member 1		
	Member 2	Member 2	
AMR	Member 1		
	Member 2	Member 2	Member 2
EMR	Member 1	Member 1	
	Member 2	Member 2	Member 2
EUR	Member 1	Member 1	
	Member 2	Member 2	Member 2
SEAR	Member 1		
	Member 2	Member 2	
WPR	Member 1		
	Member 2	Member 2	Member 2